Nonimmediate β-lactam reactions in patients with cystic fibrosis

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 4, 2012, Pages 369-375

  Whitaker, Paul ^a   Naisbitt, Dean ^b   Peckham, Daniel ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

lactam; Cystic fibrosis; Desensitisation; Hapten; Hypersensitivity; Lymphocyte

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CD4 ANTIGEN; CEFTAZIDIME; COLISTIN; IMMUNOGLOBULIN G4; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULFAMETHOXAZOLE; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; CYSTIC FIBROSIS; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; LYMPHOCYTE; MASS SPECTROMETRY; PRIORITY JOURNAL; REVIEW; SKIN TEST; T LYMPHOCYTE;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CELL PROLIFERATION; CYSTIC FIBROSIS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; MALE; PIPERACILLIN; SKIN TESTS; T-LYMPHOCYTES;

EID: 84864288665     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328355b849     Document Type: Review

References (54)

1. Wainwright BJ, Scambler PJ, Schmidtke J, et al. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature 1985; 318:384-385. (Pubitemid 16198498)
2. Tsui LC, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985; 230:1054-1057. (Pubitemid 16192696)
3. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073-1080. (Pubitemid 19231815)
4. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006; 440:477-483.
5. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969. (Pubitemid 350127838)
6. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95:1005-1015. (Pubitemid 29019052)
7. Courtney JM, Bradley J, McCaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42:525-532. (Pubitemid 46870384)
8. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-139.
9. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32:277-287. (Pubitemid 32938876)
10. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane database of systematic reviews [Meta-Analysis Review] 2005:CD002007.
11. Bergogne-Berezin E. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree [review]. Infection 1987; 15:288-294.
12. Erffmeyer JE. Adverse reactions to penicillin. Part I. Ann Allergy 1981; 47:288-293. (Pubitemid 11026376)
13. Wills R, Henry R, Francis J. Antibiotic hypersensitivity reactions in cystic fibrosis. J Paediatr Child Health 1998; 34:325-329. (Pubitemid 28355381)
14. Pleasants R, Walker T, Samuelson W. Allergic reactions to parenteral betalactam antibiotics in patients with cystic fibrosis. Chest 1994; 106:1124-1128. (Pubitemid 24309550)
15. Koch C, Hjelt K, Pedersen S, et al. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis 1991; 13 (Suppl 7):S608-S611.
16. Burrows J, Nissen L, Kirkpatrick C, Bell S. Beta-lactam allergy in adults with cystic fibrosis. J Cyst Fibros 2007; 6:297-303. (Pubitemid 46971894)
17. Matzinger P. Tolerance, danger, and the extended family [review]. Annual review of immunology 1994; 12:991-1045. (Pubitemid 24140436)
18. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A 2000; 97:14590-14595. (Pubitemid 32016620)
19. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:1249-1255. (Pubitemid 29535601)
20. Heath WR, Carbone FR. Immunology: dangerous liaisons. Nature 2003; 425:460-461.
21. Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol 2006; 118:949-956. (Pubitemid 44498760)
22. Sagel SD, Kapsner R, Osberg I, et al. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001; 164 (8 Pt 1):1425-1431. (Pubitemid 33124021)
23. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104: 72-78. (Pubitemid 29364482)
24. McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005; 175:404-412. (Pubitemid 40884344)
25. Heeckeren A, Walenga R, Konstan MW, et al. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Investig 1997; 100:2810-2815. (Pubitemid 28007550)
26. Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000; 120:518-525. (Pubitemid 30365559)
27. Mueller C, Braag SA, Keeler A, et al. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011; 44:922-929.
28. Skov M, Poulsen LK, Koch C. Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol 1999; 27:74-79. (Pubitemid 29104444)
29. Moss R. Sensitization to aztreonam and cross-reactivity with other betalactam antibiotics in high-risk patients with cystic fibrosis. J Allergy Clin Immunol 1991; 87 (1 Pt 1):78-88.
30. Moss R, Babin S, Hsu Y, et al. Allergy to semisynthetic penicillins in cystic fibrosis. J Pediatr 1984; 104:460-466. (Pubitemid 14160480)
31. Whitaker P, Meng X, Lavergne SN, et al. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol 2011; 187:200-211.
32. Lavergne SN, Whitaker P, Peckham D, et al. Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis. Chem Res Toxicol 2010; 23:1009-1011.
33. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59:1153-1160. (Pubitemid 39389467)
34. Padial A, Antunez C, Blanca-Lopez N, et al. Nonimmediate reactions to betalactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy 2008; 38:822-828. (Pubitemid 351559564)
35. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152:968-974. (Pubitemid 40704937)
36. Blanca-Lopez N, Zapatero L, Alonso E, et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 2009; 64:229-233.
37. Romano A, Di Fonso M, Artesani MC, et al. Delayed hypersensitivity to piperacillin. Allergy 2002; 57:459. (Pubitemid 34442164)
38. Luque I, Leyva L, Jose Torres M, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56:611-618. (Pubitemid 32575434)
39. Padovan E. T-cell response in penicillin allergy. Clin Exp Allergy 1998; 28 (Suppl 4):33-36.
40. Elsheikh A, Castrejon L, Lavergne SN, et al. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. J Allergy Clin Immunol 2011; 127:1543-1551.
41. El-Ghaiesh S, Monshi M, Whitaker P, et al. Characterization of the antigen specificity of T-cell clones from piperacillin hypersensitive patients with cystic fibrosis. J Pharmacol Exp Therap 2012.
42. Lafaye P, Lapresle C. Fixation of penicilloyl groups to albumin and appearance of antipenicilloyl antibodies in penicillin-treated patients. J Clin Investig 1988; 82:7-12. (Pubitemid 18262490)
43. Atanaskovic-Markovic M, Velickovic TC, Gavrovic-Jankulovic M, et al. Immediate allergic reactions to cephalosporins and penicillins and their cross-reactivity in children. Pediatr Allergy Immunol 2005; 16:341-347. (Pubitemid 40872237)
44. Romano A, Viola M, Gueant-Rodriguez RM, et al. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 2006; 354:2835-2837. (Pubitemid 43974216)
45. Atanaskovic-Markovic M, Gaeta F, Gavrovic-Jankulovic M, et al. Tolerability of imipenem in children with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol 2009; 124:167-169.
46. Vega JM, Blanca M, Garcia JJ, et al. Tolerance to aztreonam in patients allergic to beta-lactam antibiotics. Allergy 1991; 46:196-202.
47. Moss R, McClelland E, Williams R, et al. Evaluation of the immunologic crossreactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics. Rev Infect Dis 1991; 13 (Suppl 7): S598-S607.
48. Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010; 126:994-999.
49. Turvey S, Cronin B, Arnold A, Dioun A. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004; 92:426-432. (Pubitemid 39077584)
50. Legere Hr, Palis R, Rodriguez Bouza T, et al. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009; 8:418-424.
51. Burrows J, Toon M, Bell S. Antibiotic desensitization in adults with cystic fibrosis. Respirology 2003; 8:359-364. (Pubitemid 37163124)
52. Ghosal S, Taylor C. Intravenous desensitization to ceftazidime in cystic fibrosis patients. J Antimicrob Chemother 1997; 39:556-557. (Pubitemid 27196961)
53. Whitaker P, Shaw N, Gooi J, et al. Rapid desensitization for nonimmediate reactions in patients with cystic fibrosis. J Cys Fibros 2011; 10:282-285.
54. Hjortlund J, Mortz CG, Skov PS, et al. One-week oral challenge with penicillin in diagnosis of penicillin allergy. Acta dermato-venereologica 2011.